GeoVax Labs price target lowered to $10 from $14 at Roth Capital

Roth Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $10 from $14 and keeps a Buy rating on the shares. GeoVax ended Q4 with limited cash and is advancing key programs, including a Phase 3 trial for GEO-MVA expected to begin in 2H26 and continued progress for GEO-CM04S1 in immunocompromised patients, the analyst tells investors in a research note. The company also plans to initiate a 2H26 trial of Gedeptin in combination with pembrolizumab for head and neck cancer, following encouraging external study results, the firm says.